» Articles » PMID: 35846757

Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome

Abstract

The duration and severity of COVID-19 are related to age, comorbidities, and cytokine synthesis. This study evaluated the impact of these factors on patients with clinical presentations of COVID-19 in a Brazilian cohort. A total of 317 patients diagnosed with COVID-19 were included; cases were distributed according to clinical status as severe (n=91), moderate (n=56) and mild (n=170). Of these patients, 92 had acute COVID-19 at sample collection, 90 had already recovered from COVID-19 without sequelae, and 135 had sequelae (long COVID syndrome). In the acute COVID-19 group, patients with the severe form had higher IL-6 levels (p=0.0260). In the post-COVID-19 group, there was no significant difference in cytokine levels between groups with different clinical conditions. In the acute COVID-19 group, younger patients had higher levels of TNF-α, and patients without comorbidities had higher levels of TNF-α, IL-4 and IL-2 (p<0.05). In contrast, patients over age 60 with comorbidities had higher levels of IL-6. In the post-COVID-19 group, subjects with long COVID-19 had higher levels of IL-17 and IL-2 (p<0.05), and subjects without sequelae had higher levels of IL-10, IL-6 and IL- 4 (p<0.05). Our results suggest that advanced age, comorbidities and elevated serum IL-6 levels are associated with severe COVID-19 and are good markers to differentiate severe from mild cases. Furthermore, high serum levels of IL-17 and IL-2 and low levels of IL-4 and IL-10 appear to constitute a cytokine profile of long COVID-19, and these markers are potential targets for COVID-19 treatment and prevention strategies.

Citing Articles

Lipoxin A levels correlate with severity in a Spanish COVID-19 cohort: potential use of endogenous pro-resolving mediators as biomarkers.

Sanchez-Garcia S, Jaen R, Lozano-Rodriguez R, Avendano-Ortiz J, Pascual-Iglesias A, Hurtado-Navarro L Front Immunol. 2025; 15:1509188.

PMID: 39916956 PMC: 11798798. DOI: 10.3389/fimmu.2024.1509188.


Fu Tu Sheng Jin Rehabilitation Formula Mitigate Airway Inflammation, Mucus Secretion and Immune Dysfunction Induced by SARS-CoV-2 Spike Protein.

Wang B, Yu K, Zhang X, Sun X, Tang L, Shi X J Inflamm Res. 2025; 18:1053-1065.

PMID: 39871960 PMC: 11771161. DOI: 10.2147/JIR.S480112.


Polymorphisms Influence the Expression of the Fas and FasL Genes in COVID-19.

Dos Santos Brito W, de Brito W, Dos Santos Ferreira F, Santana E, Lopes J, da Silva Graca Amoras E Int J Mol Sci. 2025; 26(2).

PMID: 39859379 PMC: 11765610. DOI: 10.3390/ijms26020666.


Chronic inflammation in post-acute sequelae of COVID-19 modulates gut microbiome: a review of literature on COVID-19 sequelae and gut dysbiosis.

Iqbal N, Khan H, Khalid A, Mahmood S, Nasir N, Khanum I Mol Med. 2025; 31(1):22.

PMID: 39849406 PMC: 11756069. DOI: 10.1186/s10020-024-00986-6.


Altered immune surveillance of B and T cells in patients with persistent residual lung abnormalities 12 months after severe COVID-19.

Flores-Gonzalez J, Buendia-Roldan I, Tellez-Quijada F, Pena-Bates C, Ramon-Luing L, Castorena-Maldonado A Respir Res. 2025; 26(1):22.

PMID: 39827348 PMC: 11742501. DOI: 10.1186/s12931-025-03102-2.


References
1.
Wang F, Cao J, Yu Y, Ding J, Eshak E, Liu K . Epidemiological characteristics of patients with severe COVID-19 infection in Wuhan, China: evidence from a retrospective observational study. Int J Epidemiol. 2020; 49(6):1940-1950. PMC: 7665537. DOI: 10.1093/ije/dyaa180. View

2.
Lowe G, Rumley A, McMahon A, Ford I, OReilly D, Packard C . Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol. 2004; 24(8):1529-34. DOI: 10.1161/01.ATV.0000135995.39488.6c. View

3.
Szabo P, Dogra P, Gray J, Wells S, Connors T, Weisberg S . Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. Immunity. 2021; 54(4):797-814.e6. PMC: 7951561. DOI: 10.1016/j.immuni.2021.03.005. View

4.
Bichara C, da Silva Graca Amoras E, Vaz G, Torres M, Queiroz M, Amaral I . Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population. BMC Infect Dis. 2021; 21(1):443. PMC: 8122196. DOI: 10.1186/s12879-021-06156-x. View

5.
Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z . Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging (Albany NY). 2020; 12(13):12493-12503. PMC: 7377860. DOI: 10.18632/aging.103579. View